^
    6d
    Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=24, Recruiting, Weill Medical College of Cornell University | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)
    7d
    A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (PubMed, Leuk Lymphoma)
    Lower-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are commonly managed with erythropoiesis-stimulating agents, luspatercept, or hypomethylating agents. There were no dose-limiting toxicities. Although safe, fostamatinib demonstrated no clinical benefit, underscoring the need for alternative strategies to modulate inflammatory signaling in MDS/CMML.
    P1 data • Journal
    |
    SYK (Spleen tyrosine kinase)
    |
    Reblozyl (luspatercept-aamt) • Tavalisse (fostamatinib)
    9d
    QOL-ONE Phoenix: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant to Prior Treatments, Who Require Red Blood Cell Transfusion. (2024-519310-31-00)
    P1/2, N=22, Recruiting, Associazione Qol-One | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Reblozyl (luspatercept-aamt)
    11d
    CHASE: Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Philipps University Marburg
    New P2 trial
    |
    Winrevair (sotatercept-csrk)
    11d
    Combined Therapy with Pirfenidone, Metformin, and Mesenchymal Stem Cells Attenuates Bleomycin-Induced Pulmonary Fibrosis in Rats. (PubMed, Biomedicines)
    The combination of PFD, MET, and BM-MSCs offered superior therapeutic efficacy in treating BLM-induced pulmonary fibrosis compared to individual treatments. This multimodal approach effectively targets oxidative stress, inflammation, apoptosis, and fibrosis, suggesting strong potential for future clinical application.
    Preclinical • Journal • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • BAX (BCL2-associated X protein) • TGFB1 (Transforming Growth Factor Beta 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • MMP9 (Matrix metallopeptidase 9)
    |
    metformin • bleomycin
    11d
    SOTERIA: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (clinicaltrials.gov)
    P3, N=815, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    Winrevair (sotatercept-csrk)
    11d
    Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC (clinicaltrials.gov)
    P2, N=32, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)
    11d
    Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria (clinicaltrials.gov)
    P2, N=240, Completed, Curacle Co., Ltd. | Recruiting --> Completed | Phase classification: P2b --> P2 | Trial completion date: Sep 2024 --> Nov 2025 | Trial primary completion date: Sep 2024 --> Nov 2025
    Trial completion • Phase classification • Trial completion date • Trial primary completion date
    |
    dimethyl fumarate (CU01)
    14d
    Overexpression of the TGF-β target CCN2 in megakaryocytes: a common feature of MDS with mutated SF3B1 : Uncovering novelinsights into the bone marrow microenvironment in MDS. (PubMed, Virchows Arch)
    In aggregate, these findings may contribute to a better understanding of disease pathophysiology and help elucidate the role of potentially clinically relevant TGF-β signaling. This is particularly significant given the clinical use of agents targeting TGF-β-signaling such as luspatercept, as well as the emergence of several CCN2-targeting therapies currently undergoing clinical or preclinical evaluation with promising results.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • TGFB1 (Transforming Growth Factor Beta 1) • CTGF (Connective tissue growth factor)
    |
    RUNX1 mutation • ASXL1 mutation • SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    19d
    SAFARi: A clinical study to compare the safety and tolerability of two formulations of a new Systemic Sclerosis drug in Healthy Participants - Part B (ACTRN12625000744459)
    P1, N=33, Completed, Certa Therapeutics Pty Ltd | Not yet recruiting --> Completed
    Trial completion • Trial initiation date
    20d
    Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases (clinicaltrials.gov)
    P1/2, N=8, Terminated, M.D. Anderson Cancer Center | Completed --> Terminated; Insufficient accrual
    Trial termination
    |
    HR positive
    |
    bintrafusp alfa (M7824) • pimasertib (AS703026)
    25d
    TGF-β Inhibition Through Combinatory Strategies Suppresses Proliferation and Invasiveness in Malignant Pleural Mesothelioma. (PubMed, Int J Mol Sci)
    Data obtained clearly highlighted how TGF-β inhibition, through the silencing or treatment of MPM cells with antibody anti-TGF-β (Fresolimumab), significantly reduces cell proliferation (MTT, PCNA) and prevents metastasis, reducing EMT and decreasing the invasiveness and migration of MPM cells...Taken as a whole, targeting TGF-β will represent a starting point for future improvements in MPM management. This is particularly important as we foresee a growing increase in MPM in the coming years.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • PCNA (Proliferating cell nuclear antigen)
    |
    fresolimumab (GC 1008)